These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 30149145

  • 1. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
    Bajaj HS, Brown RE, Bhullar L, Sohi N, Kalra S, Aronson R.
    Diabetes Metab; 2018 Dec; 44(6):493-499. PubMed ID: 30149145
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.
    Irace C, Casciaro F, Scavelli FB, Oliverio R, Cutruzzolà A, Cortese C, Gnasso A.
    Cardiovasc Diabetol; 2018 Apr 09; 17(1):52. PubMed ID: 29631585
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A.
    Lancet Diabetes Endocrinol; 2017 Sep 09; 5(9):709-717. PubMed ID: 28781064
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ.
    Drugs; 2015 Jan 09; 75(1):33-59. PubMed ID: 25488697
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T, Isogawa A, Toda N, Tagawa K.
    Clin Drug Investig; 2016 Apr 09; 36(4):313-9. PubMed ID: 26914659
    [Abstract] [Full Text] [Related]

  • 8. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW.
    Vasc Health Risk Manag; 2016 Apr 09; 12():393-405. PubMed ID: 27822054
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA, Kuritzky L.
    Postgrad Med; 2014 Oct 09; 126(6):33-48. PubMed ID: 25414933
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
    Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB.
    Am J Manag Care; 2018 Apr 09; 24(8 Suppl):S138-S145. PubMed ID: 29693360
    [Abstract] [Full Text] [Related]

  • 14. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
    Martinez R, Al-Jobori H, Ali AM, Adams J, Abdul-Ghani M, Triplitt C, DeFronzo RA, Cersosimo E.
    Diabetes; 2018 Jun 09; 67(6):1182-1189. PubMed ID: 29602791
    [Abstract] [Full Text] [Related]

  • 15. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C, Lu YP, Yin L, Hocher B.
    Kidney Blood Press Res; 2019 Jun 09; 44(2):149-157. PubMed ID: 30939483
    [Abstract] [Full Text] [Related]

  • 16. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.
    Fadini GP, Zatti G, Baldi I, Bottigliengo D, Consoli A, Giaccari A, Sesti G, Avogaro A, DARWIN-T2D network.
    Diabetes Obes Metab; 2018 Jul 09; 20(7):1781-1786. PubMed ID: 29516612
    [Abstract] [Full Text] [Related]

  • 17. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C.
    Nat Rev Nephrol; 2018 Feb 09; 14(2):78-80. PubMed ID: 29307892
    [No Abstract] [Full Text] [Related]

  • 18. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D, Javor E, Lucijanić T, Skelin M.
    Ann Med; 2017 Feb 09; 49(1):51-62. PubMed ID: 27535028
    [Abstract] [Full Text] [Related]

  • 19. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC, Chang KC, Lin SJ, Chien RN, Hung MJ, Chan YY, Kao Yang YH, Lai EC.
    Cardiovasc Diabetol; 2020 Feb 12; 19(1):17. PubMed ID: 32050968
    [Abstract] [Full Text] [Related]

  • 20. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E.
    J Gastroenterol Hepatol; 2021 Apr 12; 36(4):893-909. PubMed ID: 33439540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.